Semen characteristics of individuals before and after CovishieldTM vaccination

Concern about fertility impairment after vaccination is one of the reasons for vaccine hesitancy in the population. This retrospective observational study aims to understand the impact of CovishieldTM (ChAdOx1 nCoV- 19 Corona Virus Vaccine, Recombinant) COVID-19 vaccination on ejaculate quality in fifty-three patients undergoing semen analysis between 2018 to 2021. A baseline semen profile was recorded from the subjects during their visit before the vaccination for fertility work-up. Follow-up ejaculates were provided approximately 82 (Q1:37, Q3:124) days after the second dose of vaccination. Semen characteristics such as volume, sperm concentration, sperm motility, and morphological abnormalities were recorded. Of the 53 subjects, 33 (62%) had semen characteristics above the WHO reference. In general, no significant variations in the semen parameters were observed except for a moderate decline in sperm morphology (p< 0.05). The baseline semen characteristics in 20 (38%) subjects were below the WHO reference range; however, no significant decline in the ejaculate quality was observed in their follow-up samples. Further, none of the ejaculates in both study groups were azoospermic during the follow-up evaluation. Our results affirm that CovishieldTM vaccine is not detrimental to male fertility.